If you have any questions, please reach out at [email protected]. Thank you for listening!Topics:Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 MonthsRelmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder CancerUpdate on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study

Ver todos los episodios